Pınarbaşlı Onur, Bulut Burcu, Gurbetoğlu Gülistan Pelin, Atılgan Nurdan, Sarraçoğlu Nagehan, Aybey Asuman
ILKO Pharmaceuticals, Research and Development Center, Ankara, Türkiye.
Turk J Pharm Sci. 2022 Aug 31;19(4):383-390. doi: 10.4274/tjps.galenos.2021.50432.
Racecadotril is an anti-diarrheal drug that has the indication to reduce the secretion of water and electrolytes into the intestine. It has an unpleasant taste, when administered orally. The presenting study developed a pharmaceutical racecadotril dispersible tablet, which masked the unpleasent taste using wet granulation method. For this reason, the effect of the number of ethylacrylate-methylmethacrylate copolymers (Eudragit NE 30D) in taste masking and dissolution of the finished product was investigated.
Taste-masked racecadotril granules were prepared using Eudragit NE 30D and the ratio between the amounts of racecadotril and Eudragit NE 30D involved in the formulation was optimized. The products obtained in the dispersible tablet dosage form were evaluated in terms of taste and dissolution studies. dissolution profiles of the products obtained in this study were compared with reference product Tiorfan granules for oral suspension manufactured by Bioprojet Pharma (Paris, France). A method of apparatus II (paddle), 900 mL, pH 4.5 acetate buffer + 1% sodium dodecyl sulfate (SDS) and 100 rpm at 37.0 ± 0.5°C was adopted.
Results of the studies have shown that the formulation should have Eudragit NE 30D higher than 1% by weight of racecadotril to satisfy the taste-masking ability and the formulation should have Eudragit NE 30D equal or lower than 10% by weight of racecadotril to have better release characteristic to be compatible with reference product.
Our results demonstrated that a chemically long-term stable racecadotril dispersible tablet product, whose taste is efficiently masked using wet granulation method with an acceptable release profile was obtained with Eudragit NE 30D ratio higher than 1% and equal or lower than 10% by weight of racecadotril. The developed formulation can increase patient compliance.
消旋卡多曲是一种止泻药物,具有减少水和电解质向肠道分泌的指征。口服时,它有令人不适的味道。本研究开发了一种药用消旋卡多曲分散片,采用湿法制粒法掩盖其不良味道。因此,研究了丙烯酸乙酯 - 甲基丙烯酸甲酯共聚物(Eudragit NE 30D)的用量对成品掩味和溶出的影响。
使用Eudragit NE 30D制备掩味的消旋卡多曲颗粒,并优化制剂中消旋卡多曲与Eudragit NE 30D的用量比例。对获得的分散片剂型产品进行口感和溶出度研究评估。将本研究获得的产品溶出曲线与法国巴黎Bioprojet Pharma生产的对照产品口服混悬液Tiorfan颗粒进行比较。采用装置II(桨法),900 mL,pH 4.5醋酸盐缓冲液 + 1%十二烷基硫酸钠(SDS),在37.0 ± 0.5°C下100 rpm。
研究结果表明,制剂中Eudragit NE 30D的重量应高于消旋卡多曲的1%,以满足掩味能力;制剂中Eudragit NE 30D的重量应等于或低于消旋卡多曲的10%,以具有更好的释放特性,从而与对照产品兼容。
我们的结果表明,使用湿法制粒法有效地掩盖了味道,并获得了具有可接受释放曲线的化学长期稳定的消旋卡多曲分散片产品,其中Eudragit NE 30D的比例高于消旋卡多曲重量的1%且等于或低于10%。所开发的制剂可提高患者的依从性。